Showing results (171-180 of 441) with videos related to
Sort By:
Pageof 45
Journal of Neuro-Oncology|December 29, 2011
Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitorsSamuel A Goldlust, Robert Cavaliere, Herbert B Newton, et al.Journal of Neuro-Oncology|May 8, 2014
Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastomaMohamed A Hamza, Jacob J Mandel, Charles A Conrad, et al.BMC Cancer|March 22, 2023
Feasibility and preliminary efficacy of a virtual reality intervention targeting distress and anxiety in primary brain tumor patients at the time of clinical evaluation: Study protocol for a phase 2 clinical trialAmanda L King, Alvina A Acquaye-Mallory, Elizabeth Vera, et al.Neuro-Oncology|February 4, 2015
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trialKathleen M Schmainda, Zheng Zhang, Melissa Prah, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastomaMichael E Scheurer, E Amirian, Yumei Cao, et al.Cancers|July 2, 2021
Targeting CDK9 for the Treatment of GlioblastomaAlice Ranjan, Ying Pang, Madison Butler, et al.Journal of Neuro-Oncology|July 16, 2016
Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying)Quinn T Ostrom, Haley Gittleman, Carol Kruchko, et al.Cancers|June 25, 2020
Metabolic Landscape of a Genetically Engineered Mouse Model of IDH1 Mutant GliomaVictor Ruiz-Rodado, Tomohiro Seki, Tyrone Dowdy, et al.Neuro-Oncology|January 31, 2009
Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factorsTerri S Armstrong, Yumei Cao, Michael E Scheurer, et al.Neuro-Oncology|July 10, 2010
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label studyW K Alfred Yung, James J Vredenburgh, Timothy F Cloughesy, et al.Pageof 45